Led by researcher Ben Goudey, the team used artificial intelligence (AI) technology to identify a set of proteins in blood that could predict amyloid-beta concentration in spinal fluid.
Previous studies indicated that amyloid-beta is a biological marker associated with Alzheimer’s.
It was found that people with mild cognitive impairment that were predicted to possess an abnormal amyloid concentration in their spinal fluid were 2.5 times more likely to develop the disease.
